DYRK4 Knockout HEK293T Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely used human embryonic kidney HEK293T host cell line. This product is designed for loss-of-function studies of the human DYRK4 gene, which encodes a dual-specificity kinase implicated in cell cycle regulation. The polyclonal population comprises a heterogeneous mixture of cells harboring diverse CRISPR-mediated disruptions at the target locus, creating a robust model system for investigating DYRK4-dependent signaling without the need for clonal isolation. Researchers can leverage this knockout pool to assess global functional consequences of DYRK4 ablation in a reproducible and high-throughput manner.
The HEK293T host cell line originates from human embryonic kidney epithelial cells immortalized by SV40 large T antigen transformation, rendering them highly permissive for viral production, recombinant protein expression, and gene editing applications. These cells exhibit robust proliferation, excellent transfection efficiency, and ease of culture, making them a staple in molecular biology and drug discovery workflows. Their well-characterized background facilitates straightforward interpretation of phenotypic changes following gene disruption, and the polyclonal knockout format offers a practical approach for rapid functional screening without clonal expansion.
DYRK4 phosphorylates cyclin D1 at residue Thr286, generating a phosphodegron motif that is recognized by the DDB1-CUL4A E3 ubiquitin ligase complex. This post-translational modification targets cyclin D1 for ubiquitin-mediated degradation, thereby reducing its availability to activate cyclin-dependent kinases CDK4 and CDK6. Consequently, the retinoblastoma protein RB1 remains hypophosphorylated, repressing E2F transcription factor activity and inhibiting the G1/S transition. DYRK4 thus functions as a negative regulator of cell cycle progression, integrating signals that control timely entry into S phase. Its expression is subject to tissue-specific transcriptional regulation, notably observed in testis, though upstream activating pathways remain incompletely characterized.
In the HEK293T cellular context, DYRK4 knockout is anticipated to elevate cyclin D1 protein levels, promoting enhanced CDK4/6 kinase activity and accelerated G1/S transition. This dysregulation provides a valuable system for examining cell cycle control mechanisms and their aberration in cancer, where DYRK4 may exert a tumor-suppressive role. Additionally, the model supports investigations into ubiquitin-mediated proteolysis and its impact on proliferation. The polyclonal nature of the knockout population captures a spectrum of gene disruption severities, enabling researchers to observe graded phenotypes that may more closely reflect physiological or pathological heterogeneity.
This knockout product is ideally suited for a range of experimental applications, including Western blotting to monitor cyclin D1 abundance, flow cytometric analysis of cell cycle distribution, co-immunoprecipitation to assess DYRK4 interaction with DDB1, and ubiquitination assays to track cyclin D1 turnover. Proliferation assays and RT-qPCR profiling of cell cycle genes further validate functional outcomes. The model supports drug discovery efforts targeting DYRK family kinases, creation of disease-relevant cellular models via gene editing, and systematic analysis of polyclonal knockout effects in the versatile HEK293T background. For additional details or customization, please contact Ascent Research.
